Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
NCT01597531 on ClinicalTrials.gov · last registry update 2018-02-05
Stopped early, having planned 1 participants. The sponsor logged completion for June 2014. Primary outcome, as filed: Type 2 diabetes remission. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- TERMINATED
- Phase
- P4
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- East Carolina University
- Sponsor type
- Other
- Enrollment
- 1
- Started
- 2012-06
- Primary completion
- 2014-06 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Type 2 diabetes remission
Conditions studied
Type 2 Diabetes · Gastric Banding
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.